High-dose gadoteridol in MR imaging of intracranial neoplasms.

Abstract

Twelve patients with a high suspicion of brain metastases by previous clinical or radiologic examinations were studied in a phase III investigation with magnetic resonance (MR) imaging at 1.5 T after a bolus intravenous injection of 0.1 mmol/kg gadoteridol followed at 30 minutes by a second bolus injection of 0.2 mmol/kg gadoteridol. All lesions were best demonstrated (showed greatest enhancement) at the 0.3-mmol/kg (cumulative) dose, with image analysis confirming signal intensity enhancement in the majority of cases after the second gadoteridol injection. More lesions were detected with the 0.3-mmol/kg dose than with the 0.1-mmol/kg dose, and more lesions were detected with the 0.1-mmol/kg dose than on precontrast images. In this limited clinical trial, high-dose gadoteridol injection (0.3-mmol/kg cumulative dose) provided improved lesion detection on MR images specifically in intracranial metastatic disease.

• Authors: V M Runge, J E Kirsch, V J Burke, A C Price, K L Nelson, G S Thomas, B L Dean, C Lee
• Journal: Journal of magnetic resonance imaging : JMRI (J Magn Reson Imaging) 1992 Jan-Feb Vol. 2 Issue 1 Pg. 9-18 ISSN: 1053-1807 [Print] United States
• PMID: 1623287 (Publication Type: Journal Article)

Chemical References

• Contrast Media
• Heterocyclic Compounds
• Organometallic Compounds
• gadoteridol
• Gadolinium

Topics

• Adult
• Aged
• Brain Neoplasms (diagnosis, secondary)
• Contrast Media
• Female
• Gadolinium
• Heterocyclic Compounds
• Humans
• Magnetic Resonance Imaging
• Male
• Middle Aged
• Organometallic Compounds